Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Cardiome Pharma
CRME

Buy Cardiome Pharma (CRME) Stock

CRME
See CRME stock price and Buy/Sell Cardiome Pharma with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
CRME

Cardiome Pharma (CRME)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Cardiome Pharma (CRME)

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to ...Read more
Market Cap
$27.8M
1 Year High
$2.79
Volume
1 Year Low
$0.21
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch CRME stock

Cardiome Pharma stock rating

What analysts recommend for CRME stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
3

Cardiome Pharma price target

What analysts think CRME will be worth
Low $0
High $2.79
Current $0
Target $0.42

Cardiome Pharma earnings

The value each share was expected to gain vs. the value that each share actually gained
0
-0.03
-0.07
-0.1
Q1 2020
Q2 2020
Q3 2020
Q4 2020

Expected EPS
Q4 2020
-$0.09
Actual EPS
Q4 2020

Buy Cardiome Pharma (CRME) Stock

CRME
See CRME stock price and Buy/Sell Cardiome Pharma with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch CRME stock
  • taradawn avatar
  • jdub503 avatar
  • Zhangbao421 avatar
  • dmehungry avatar
  • jolaoye avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.